Skip to Content

Vidaza (azacitidine) Disease Interactions

There are 4 disease interactions with Vidaza (azacitidine):


Azacitidine (applies to Vidaza) hepatic tumors

Major Potential Hazard, Moderate plausibility.

The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.


Azacitidine (applies to Vidaza) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.


Azacitidine (applies to Vidaza) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.


Miscellaneous antineoplastics (applies to Vidaza) anemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia

Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.

Vidaza (azacitidine) drug interactions

There are 124 drug interactions with Vidaza (azacitidine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.